New Study Says I Was Wrong About NMN and NR?

Key Takeaways

• Small Bergen study favors NR; larger trial finds parity
• Gut microbes convert NR and NMN to nicotinic acid
• Blood NAD rises, but functional outcomes stay unchanged
• Meta‑analyses show no muscle or metabolic improvements in seniors
• Exercise may be more effective than expensive NAD precursors

Pulse Analysis

The NAD‑boosting market has exploded as researchers linked declining nicotinamide adenine dinucleotide levels to age‑related dysfunction. Early discoveries by Charles Brenner positioned nicotinamide riboside (NR) as a direct NAD precursor, while David Sinclair’s work popularized nicotinamide mononucleotide (NMN). Both compounds command premium prices and fuel a competitive narrative that one is superior for cellular health. Recent human trials, however, reveal that the rivalry may be overstated: a modest six‑person crossover study reported a larger NAD increase with NR, yet a substantially larger, double‑blind study showed NR and NMN produce comparable NAD elevations, eroding the claim of a clear winner.

Beyond the headline numbers, emerging mechanistic research highlights the gut microbiome as a decisive factor in NAD precursor metabolism. Isotope‑labelled studies and ex‑vivo fecal assays demonstrate that orally administered NR and NMN are frequently de‑acetylated by intestinal bacteria into nicotinic acid, which then feeds the Preiss‑Handler pathway to regenerate NAD. This indirect route suggests that the expensive molecules may act largely as pro‑drugs for a cheaper vitamin B3 form, challenging the premise that intact NR or NMN reaches target tissues more efficiently than standard nicotinic acid or nicotinamide.

Clinically, the story remains sobering. Meta‑analyses of randomized trials in older adults show no significant gains in muscle mass, strength, gait speed, or metabolic markers despite measurable NAD boosts. A long‑COVID trial echoed these results, with elevated NAD failing to improve fatigue or cognitive symptoms. Consequently, the cost‑benefit calculus for NR and NMN is unfavorable when compared with proven interventions such as regular exercise, which naturally sustains NAD pools without the expense or reliance on microbial conversion. Stakeholders should therefore prioritize interventions with demonstrated functional outcomes over unproven supplement hype.